Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Pfizer1 enrolled

Overview

This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.

No sampling as no subjects are enrolled

Study Type

OBSERVATIONAL

Enrollment

Conditions

Invasive Pneumococcal Disease

Interventions

No interventionOTHER

No intervention

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population. Exclusion Criteria: None

Locations (1)

Kaiser Permanente Vaccine Study Center

Oakland, California, United States

Outcomes

Primary Outcomes

Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.